Immuron Director resignation
September 23 2021 - 11:00PM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian
biopharmaceutical company focused on developing and commercializing
oral immunotherapeutic products for the prevention and treatment of
gut pathogens, today received the resignation of Mr Peter
Anastasiou.
Mr Anastasiou joined the Board in May 2015 after
becoming a major shareholder in 2013 and was appointed Vice
Executive Chairman in August 2015 to assist US market development
opportunities and supporting key programs at Immuron.
Mr Anastasiou commented that “Small companies
rarely get an opportunity to acquire a transformative asset of
national significance. Our shareholders have lost a chance to
contribute to the advancement of very safe Covid vaccine. As a
result, I have decided to step down despite my confidence in
Immuron technology and the strong financial position the company is
in.”
The Board is enormously grateful to Peter for
all of his hard work, energy and expertise over the last few years.
He has made a significant contribution in securing Immuron's long
term future and leaves the Company in a substantially significantly
stronger position than when he joined the Board. The Company’s
strong cash reserves and pipeline of exciting projects promise a
bright future and we look forward to continuing our relationship
with Peter in his capacity as a significant Shareholder.
This release has been authorised by directors of
Immuron Limited.
COMPANY
CONTACT:Dr Jerry
Kanellos, Ph.D.Chief Executive OfficerPh: +61 (0)3 9824
5254info@immuron.com |
|
|
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jul 2023 to Jul 2024